A retrospective study of 96 patients identified the CAR-HEMATOTOX risk score as a predictor of severe neutropenia and thrombocytopenia after CAR-T therapy. Researchers reported that patients in higher-risk strata experienced dramatically higher rates of both complications. The work targets a major clinical management challenge in CAR-T care—anticipating hematologic toxicities early enough to adjust monitoring intensity, supportive measures, and potentially treatment scheduling. A risk score that is practical to apply can help standardize decisions across centers. The next phase will be prospective validation and calibration across CAR-T product types, lymphodepletion regimens, and patient comorbidity profiles.